Esg Rating

Incheon – November 03, 2026 -- Samsung Biologics (KRX: 207940.KS) has earned an ESG Risk Rating score of 9.0 from Morningstar Sustainalytics, placing the contract development and manufacturing organization (CDMO) among the top 0.5% of companies assessed in the pharmaceuticals industry.

Samsung Biologics moves from 'Low Risk' to the lowest of five risk categories

The company advanced to 'Negligible Risk' from its previous 'Low Risk' rating. Under Sustainalytics' methodology, scores below 10 indicate a negligible level of unmanaged ESG risk, and lower scores reflect lower overall risk.

Morningstar Sustainalytics, an independent ESG research and ratings provider, assesses approximately 16,000 companies worldwide. It measures their exposure to material ESG risks and how effectively those risks are managed.